PARP1/c-Met-IN-2

PARP1/c-Met-IN-2 is a highly potent, orally active, PARP1 (IC50 = 21.8 nM) and c-Met (IC50 = 30.2 nM) dual inhibitor. PARP1/c-Met-IN-2 can elevate the expression level of γH2AX, cause DNA damage. PARP1/c-Met-IN-2 exhibits remarkable anti-tumor efficacy in the Olaparib (HY-10162) -resistant HCT116 (HCT116OR) xenograft models. PARP1/c-Met-IN-2 can be used for the study of Colon Cancer[1].

Product Specifications

UNSPSC

12352005

Target

C-Met/HGFR; DNA/RNA Synthesis; PARP

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

N#CC1=CC(C2=NN(C(C=C2)=O)CCOC3=C4C=CC(N5CCN(CC5)C(C6=CC7=C(C(C(N)=O)=CC=C7)O6)=O)=CC4=NC=C3)=CC=C1.Cl

Molecular Formula

C36H30ClN7O5

Molecular Weight

676.12

References & Citations

[1]Sun Z, et al. Discovery of a novel benzofuran-7-carboxamide-based PARP1/c-Met dual inhibitor for addressing c-Met amplification-mediated PARP1i acquired-resistance. Eur J Med Chem. 2025 Dec 15;300:118164.